Buzz on the Bullboards: A Bigger Picture for Smaller Caps

Stockhouse Editorial

2 Comments| March 24, 2022

(Image via Blackberry Ltd.)

The business of war weighs on the minds of investors and companies today. It is not just that, but the push to re-emerge from the COVID-19 pandemic to supply chain issues, business has been adapting.

Take BlackBerry Limited (TSX: BB, Forum), who announced this week that it is deepening its collaboration in China with Marelli, a Tier 1 global automotive supplier. Marelli has chosen the BlackBerry QNX Neutrino RTOS and BlackBerry QNX Hypervisor to power their Cockpit Domain Controller (pictured above), a critical in-vehicle system featuring Infotainment and Digital Cluster functions.

Security is also top-of-mind and Canadian developer Patriot One Technologies Inc. (TSX:PAT, Forum)’s principal business is to commercialize a system to detect concealed weapons utilizing radar technologies.

To advance its business, Patriot One just closed its public offering for total gross proceeds of $6,446,070 (CAD).

The company issued 10,743,450 units at a price of $0.60 per unit. Each unit consists of one common share and one share purchase warrant.

The offering was conducted through Echelon Wealth Partners Inc. as sole agent and bookrunner. The agent received a cash fee of $439,310 (CAD) and 732,183 common share purchase warrants.

The proceeds will be used for working capital and general corporate purposes.

(Image via Datametrex AI Ltd.)

Good buzz for Datametrex AI Ltd. (TSXV:DM, Forum), the AI and Machine Learning company was recently recognized by CIOReview, a leading digital and print technology magazine, praised as the most promising Canadian tech company for 2022.

Through its wholly owned subsidiary, Nexalogy, the company’s AI-based technology is currently being used by governments for data mining and social media conversation analysis that is critical in the fight to stop the spread of misinformation and propaganda in the world, notably in China and Russia.

Datametrex will continue to focus on developing AI-powered solutions as it extends its footprint into new industries such as telehealth and electric charging.

“At Datametrex, we continue our efforts to facilitate ground-breaking technologies for companies across the globe. We pride ourselves in providing tools that our clients can use to visualize customer and stakeholder data in order to make predictive analysis, mitigate risk and improve their bottom line,” said Marshall Gunter, CEO of Datametrex.

Tilray Brands Inc. (NASDAQ: TLRY, Forum) is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people’s lives for the better – one person at a time.

Tilray Brands delivers on this mission by inspiring and empowering the worldwide community to live their very best life and providing access to products that meet the needs of their mind, body, and soul while invoking wellbeing.

Tilray has expanded its medical cannabis offering and launched the first EU GMP medical cannabis oil products in Malta.

Tilray’s EU-GMP medical cannabis products are now available in pharmacies across Malta, providing patients with safe and reliable access to high-quality medical cannabis.

Denise Faltischek, Tilray’s Chief Strategy Officer, and Head of International Business, said, “Demand for medical cannabis in Malta is growing rapidly and we are incredibly proud to service patients with the high-quality medical cannabis products they rely on and in the formats they prefer.”

In Malta, patients may obtain prescriptions for medical cannabis and a medical cannabis card through family doctors. Medical cannabis cards are issued by Malta’s Superintendent of Public Health.

Tilray has a pioneering track record as a company committed to making EU GMP-certified, pharmaceutical-grade medical cannabis products available to patients in need around the world and was the first to successfully export medical cannabis from North America and import medical cannabis products into the EU in 2016.

Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, and Symbios.

Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany.

Today, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents.

(Image via Sugarbud Craft Growers Corp.)

Calgary-based, consumer-driven boutique craft cannabis company Sugarbud Craft Growers Corp. (TSX-V: SUGR, Forum) is a leading craft cannabis company focused on the cultivation and production of cannabis products.

Focused on the cultivation and production of high-quality, genetically-diverse, select-batch connoisseur cannabis products, Sugarbud has announced the launch of Bahama Blizzard #11 in British Columbia.

Total THC will range between 210-260 mg/g and a total terpene profile of between 2% to 4%.

“We are delighted to be expanding our existing product portfolio in British Columbia with this very unique and exclusive cultivar,” stated Sugarbud’s CEO, John Kondrosky.

“We continue to develop and expand our product offering with new and exciting cultivars that deliver on potency, terpene content, flavor and aroma. Bahama Blizzard #11 is yet another fine example of our commitment to consumer satisfaction and the house-style and craftsmanship that has come to define Sugarbud Craft Cannabis – visually appealing and dense sugary bud structure, exceptional terpene forward aromas and smooth flavors,” concluded Mr. Kondrosky.

The company expects Bahama Blizzard #11 3.5g Dried Flower to be available online and at government-run BC Cannabis Stores and private retailers throughout BC in early Q2, 2022.

What the "Buzz"

Our Bullboards have up to 2 Million pageviews a day. Get the inside scoop on conversations around the most significant trends and stock appreciations in our weekly wrap up.

Get "Buzz on the Bullboards" delivered to your inbox every Thursday!

Buzz on the Bullboards | Sign Up Here

City View Green Holdings Inc. (CSE: CVGR, Forum) is a consumer packaged goods company focused on the development of cannabis-infused edibles.

The company has announced a $1 million (CAD) non-brokered private placement and will offer up to $20 million (CAD) units priced at $0.05.

Each unit consists of one common share and one warrant and entitles the holder to purchase one common share for $0.10 for two years from the closing date, subject to acceleration with 30 days’ notice.

The company will use the proceeds for general working capital. It closed the first tranche earlier today through the issuance of 9.6 million units for total gross proceeds of $480,000 (CAD).

Rob Fia, the company’s CEO, invested $100,000 (CAD) in the first tranche.

The company has also settled debt of $88,324.98 (CAD) with arm’s length creditors by issuing 1,261,784 common shares priced at $0.07.

A company that provides turnkey coronavirus screening solutions to the private sector is boosting its COVID-19 testing business.

ScreenPro Security Inc. (CSE: SCRN, Forum) announced this week that it had received four COVID-19 testing contracts from well-known film production companies in Vancouver and Toronto.

Though the Covid environment is changing, testing is strong with a 50% increase in added productions compared to February and over 20% in weekly growth this month. The Company is now providing testing for a total of 11 film production companies.

ScreenPro CEO Lena Kozovski said in a media release on this news that the company is riding continued momentum with COVID-19 testing within the film and production industry.

“With the additional film productions being added, we continue to build our brand and reputation within the industry.”

This is in addition to seven new COVID-19 testing contracts from film production companies in Vancouver and Toronto in late February 2022.

ScreenPro Security also made news recently when it completed the acquisition of all the issued and outstanding shares of Add Biomedical Inc., a screening company with a focus on breast cancer detection and veterinary diagnostics. It is working on commercializing its products in North America, which would be aided by ScreenPro’s relationships in distribution and logistics.

Under an amended Share Purchase Agreement with Add Biomedical, ScreenPro will pay $3.3 million (CAD) in units.

ScreenPro issued 33,000,000 units. Each unit is comprised of one common share priced at $0.15 and one common share purchase warrant exercisable at $0.20 for two years from closing.

Now that the acquisition of Add Biomedical is finalized, CEO Kozovski called this expansion a strategic acquisition that advances the company further into the health screening industry.

“We are excited for this new addition of the company and look forward to sharing our future plans.”

Add Biomedical has become a wholly owned operating subsidiary of ScreenPro. Michael Yeung has been appointed as the new director of Add Biomedical, Lena Kozovski as Chief Executive Officer and Paul Haber as Chief Financial Officer.

(Image via ScreenPro Security Inc.)

TAAT Lifestyle & Wellness Ltd. (CSE: TAAT, Forum) markets a tobacco-free and nicotine-free alternative to traditional cigarettes available in “Original”, “Smooth”, and “Menthol” varieties.

The company reported this week that all TAAT products are now available in more than 2,500 retail stores in the United States.

The company has added an average of approximately 45 new US stores per week in 2022.

TAAT continues to leverage its network of distributors to further expand its store count and cultivate a strong presence at the point of sale to encourage first-time and repeat purchases of TAAT products in place of tobacco cigarettes.

TAAT founder Joe Deighan commented on the news.

“Now that we are a proven brand in the tobacco category, retailers are far more willing to carry TAAT in their stores, maintain an ample supply and place TAAT in high-visibility spots for consumers to see. With consumers continuing to walk into stores across the country looking for TAAT, retailers are recognizing that it is important for our product to be placed in a prime space on their cigarette display racks. This is not just to give the customers what they want, it’s also because our retailers make significantly better profit margins on TAAT than they do on packs of tobacco cigarettes such as Marlboro. That is, they have a financial incentive to convert their clientele to TAAT because doing so will be significantly more lucrative for them in the long run. By offering a win-win all around for wholesalers, retailers, and consumers alike, TAAT has enjoyed continued growth of its market share as an innovative provider of a better choice for current smokers.”

Reliq Health Technologies Inc. (TSX-V:RHT, Forum) specializes in developing Software-as-a-Service (SaaS) solutions for remote patient monitoring, telemedicine, and care collaboration. Reliq’s powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits.

RHT signed five new contracts with three primary care practices and two home health agencies in the US.

The company is also expanding its mental health care capabilities to include Collaborative Care Management (CoCM).

“We are pleased to be adding these five new clients,” said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc. “These providers will add over 2,000 new patients to our iUGO Care platform. The contracts include a one-time payment of $400,000 for hardware (medical monitoring devices) and are expected to generate an average recurring revenue of over $70 per patient per month. Onboarding is expected to begin next month.

Our CoCM module allows primary care physicians and specialists to proactively care for patients with behavioural, mental health or psychiatric conditions including addiction. CoCM is an additional level of care that can be offered to patients who aren’t responding to Behavioural Health Integration services alone. The Centers for Medicare and Medicaid Services (CMS) reimburse clinicians an average of $230 per patient per month for CoCM services, in addition to any payments the provider is receiving from CMS for other virtual care services provided to the patient including Remote Patient Monitoring (RPM) and Chronic Care Management (CCM). CoCM provides a new revenue stream for clinicians while improving care for patients with the most challenging mental health and addiction issues.”

Turning to this week’s Investor Pulse Poll, we want to know what you may be already thinking – if Russia’s invasion of Ukraine has the possibility of starting the next World War, how far will the markets fall? Let us know your thoughts on this by clicking the image below to cast your vote.